Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European ..
Atezolizumab is now approved for the adjuvant treatment of NCSLC expressing PD-L1≥1%. The approval is based on the IMpower010 study. The FDA has granted approval to atezolizumab (Tecentriq) as adjuvant treatment following surgery and platinum-based chemothe..
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 outbreak that began in 2019 and spread rapidly across the world has been demonstrated to cause viral pneumonia, acute respiratory distress syndrome (ARDS) and multi-organ system failure . Given the lac..
Alprostadil combined with a-LA is better than alprostadil monotherapy in the treatment of diabetic nephropathy (DN), suggests a study published in the American Journal of Translational Research.A team of researchers from China conducted a study to inv..
Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. This meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost nonrespo..
For patients with childhood-onset systemic lupus erythematosus (SLE), rituximab (RTX) use among pediatric nephrologists and rheumatologists for the treatment of proliferative lupus nephritis (LN) refractory to induction therapy for LN flare following remission..
Pembrolizumab prolonged OS compared with placebo for certain patients with advanced hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.Pembrolizumab (Keytruda, Merck) also extended PFS and induced a higher objective respo..
Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, mul..
Combination cetuximab and avelumab seems feasible as rechallenge therapy in patients with chemotherapy-refractory, RAS wild-type (WT), metastatic colorectal cancer (mCRC), according to results published in JAMA Oncology. In the phase 2 CAVE trial (Clinic..